Research programme: PCSK9 inhibitors - Draupnir Bio
Alternative Names: PCSK9 modulatorsLatest Information Update: 04 Jul 2024
At a glance
- Originator University of Aarhus
- Developer Draupnir Bio; University of Aarhus
- Class Antihyperlipidaemics; Cardiovascular therapies; Small molecules
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cardiovascular disorders
Most Recent Events
- 04 Jul 2024 Preclinical development is ongoing in Denmark (PO) (Draupnir Bio pipeline, July 2024)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Denmark (PO)
- 29 Sep 2016 Draupnir Bio has patent protection for PCSK9 inhibitors in Cardiovascular disorders by September 2016